Clascoterone

浙江万晟近日决定更名。提及浙江万晟，许多人可能并不那么熟悉，但若提到“蔓迪”，相信大家就不陌生了。这款近年来风头正劲的生发类产品，其品牌知名度已远超所属公司的知名度。而在近日，浙江万晟决定，将公司直接更名为“浙江三生蔓迪药业有限公司”，正式将“蔓迪”二字刻在公司的门楣之上，也刻进了未来发展的基因里。对于更名的决定，三生制药表示，此次更名将更好落实企业发展规划，进一步放大蔓迪品牌的影响力，让广大消费者不仅熟悉作为产品的蔓迪，也更加了解作为企业的蔓迪。01“扶正”蔓迪，10亿只是开始2022年三生制药的年报显示，蔓迪实现销售收入8.91亿元，2023年的中报中，蔓迪同比增长35.3%，按此速度若保持至年底，蔓迪去年全年销售收入突破10亿元应该不成问题。10亿元往往是判断一款药物是否为重磅产品的一道分水岭。在这一节点上选择将产品名称与企业名称统一，三生蔓迪显然没有将10亿元看作蔓迪的“终点”，而是一个新的“起点”。2001年，蔓迪作为国内最早的脱发药品之一上市，治疗男性型脱发和斑秃。2018 年，公司对产品进行升级，推出拥有PBS专利技术的蔓迪第三代5%米诺地尔酊，解决了米诺地尔在常温下长期保存难以确保稳定性的难题。2017-2022 年，蔓迪的营收年复合增长率高达57%，市场占有率超过70%。这一成绩的背后除了稳固的医院渠道，对电商的大力拓展功不可没。数据显示，蔓迪电商渠道的贡献占比已超过60%，但增速仍高达64%。从线上布局来看，蔓迪从阿里、京东等传统电商平台，正在持续向抖音商城、小红书等新电商平台扩展，力图打造多元化、精细化的运营模式，精准触达和转化潜在意向客户，继续提升电商平台的销售规模。而随着品牌影响力的不断提升，蔓迪的内涵也突破了单一的米诺地尔药物，而是围绕“生发”的概念，不断丰富产品矩阵，进一步开拓市场空间。为了向毛发相关的生活场景渗透，公司相继开发出蔓迪洗发水、蔓迪小密梳，还有专门针对发际线和发缝精细化升级的蔓迪精灵瓶等系列产品。今年年初，蔓迪泡沫剂宣布获批上市，并取得OTC资格。该产品是目前国内唯一获批上市米诺地尔泡沫剂型，具有更好的透皮速度和头皮下蓄积率、更温和的头皮耐受性，将进一步提升蔓迪的市场竞争优势。02核心产品品牌反哺公司发展公司与产品使用同一品牌资产，这一安排在医药行业里很容易让人联想到云南白药和片仔癀等兼具医药与消费品属性的企业。然而，不同于云南白药让公司品牌向产品品牌赋能的路径，此次浙江万晟更名为“三生蔓迪”，实则是核心产品品牌“反哺”公司的一次“反其道而行”。或许将其与美妆巨头进行类比更容易让人理解。纵观国际知名的美妆集团，以单个品牌命名集团名字的比比皆是，例如欧莱雅、雅诗兰黛、资生堂等，都是以集团中王牌品牌作为公司名称的例证。从企业发展脉络来看，这些成立少则几十年，多则百余年的企业，起家都靠单个品牌打响知名度，赢得了市场和口碑，在站稳脚跟后，顺势扩张规模从一家单品牌公司通过内部孵化或者外部收购，发展至多品牌大型集团。以雅诗兰黛集团为例，1946年，雅诗兰黛夫人创立了雅诗兰黛，以自己的名字命名公司。如今，雅诗兰黛旗下除了同名品牌、还有海蓝之谜、祖马龙、倩碧等多个知名大牌。分析人士指出，将公司冠以核心品牌的名称，有助于将公司的平台价值进行放大，进而带动整个公司的发展，帮助公司的其他品牌为更多消费者所熟知。更名三生蔓迪后，浙江万晟是否后续会有更多的动作？时间将给出答案。03强化三生链接，明确支柱定位事实上，除了将蔓迪放入公司名以外，此次浙江万晟更名还有一个看点便是加入了“三生”二字。此举不但进一步强化了三生蔓迪与母公司三生制药之间的链接，也明确了其作为三生制药发展支柱的定位。随着蔓迪近年来的崛起，毛发皮肤领域与肾科、肿瘤与血液，以及自身免疫性疾病一起，已成为三生制药发展的四大支柱领域之一。一方面，三生制药在脱发领域还远未到开发的极限。据卫健委统计，2022 年国内脱发人群人数超2.5亿，而目前蔓迪的渗透率仅占 2–3%，增长潜力依然巨大。Frost & Sullivan预测，中国脱发市场规模预计在2026年将达到412亿元，年均复合增长率接近12%。在所有脱发类型中，男性型脱发（雄脱）是最为常见的类型之一。《中国人雄激素性脱发诊疗指南》 指出，米诺地尔对于雄脱的防脱发及改善效果、安全性都优于其他种类治疗药物，获得指南最高推荐等级。在《女性雄激素性脱发诊断与治疗中国专家共识(2022年版)》中，5%米诺地尔在女性雄脱中亦获得最高推荐等级。另一方面，近年来三生制药围绕毛发皮科领域也在进行一系列的布局。2022年，三生制药与意大利制药公司Cosmo签订合作协议，获得用于治疗痤疮适应症的全球首款外用雄激素受体抑制剂1%克拉考特酮（Winlevi）在大中华区开发和商业化的独家权利。作为FDA 40年来批准的首个新机制痤疮用药，Winlevi在美国已经获得了皮肤科医生的广泛认可，自2021年12月上市以来有1.5万名医生开具超过67万张处方，已成为美国处方量最大的痤疮治疗用药。据悉，该药目前在中国所进行的桥接试验和未来的商业化都由浙江万晟——也就是未来的三生蔓迪操刀。而在今年年初，由浙江万晟生产的他克莫司两个剂型的产品视同通过仿制药一致性评价获国家药品监督管理局批准上市。业内人士指出，他克莫司通过一致性评价后，将有资格参与可能到来的集采，从而占领更大的市场份额。可见，浙江万晟如今作为三生制药毛发皮科核心平台的定位已经十分清晰，更名“三生蔓迪”后，这一信息将更为明确和顺畅地传递到市场。在颜值经济爆发的当下，三生蔓迪无疑将是三生制药一张闪亮的新名片。精彩推荐CM10 | 集采 | 国谈 | 医保动态 | 药审 | 人才 | 薪资 | 榜单 | CAR-T | PD-1 | mRNA | 单抗 | 商业化 | 国际化 ｜ 猎药人系列专题 | 出海启思会 | 声音·责任 | 创百汇 | E药经理人理事会 | 微解药直播 | 大国新药 | 营销硬观点 | 投资人去哪儿 | 分析师看赛道 | 药事每周谈 | 医药界·E药经理人 | 中国医药手册创新100强榜单 | 恒瑞 | 中国生物制药 | 百济 | 石药 | 信达 | 君实 | 复宏汉霖 ｜翰森 | 康方生物 | 上海医药 | 和黄医药 | 东阳光药 |  荣昌 | 亚盛医药 | 齐鲁制药 | 康宁杰瑞 | 贝达药业 | 微芯生物 | 复星医药 ｜再鼎医药｜亚虹医药跨国药企50强榜单 | 辉瑞 | 艾伯维 | 诺华 | 强生 | 罗氏 | BMS | 默克 | 赛诺菲 | AZ | GSK | 武田 | 吉利德科学 | 礼来 | 安进 | 诺和诺德 | 拜耳 | 莫德纳 | BI | 晖致 | 再生元

Both newly approved and well-established treatments recommended ROSEMONT, Ill., Jan. 31, 2024 /PRNewswire/ -- Acne is the most common skin condition in the United States, affecting nearly 50 million Americans each year, with symptoms usually beginning in puberty. Acne affects 85% of adolescents and can also often begin or continue in adulthood, especially in women. To help ensure that people with acne get the best possible treatment, the American Academy of Dermatology (AAD) has published updated guidelines of care for the management of acne in adults, adolescents, and children over the age of 9 in the Journal of the American Academy of Dermatology. Continue Reading "These guidelines provide important updates to the 2016 AAD acne guidelines, including discussion of new topical medications, which are directly applied to the skin, and systemic treatments, which are taken by mouth," said board-certified dermatologist John S. Barbieri, MD, MBA, FAAD, co-chair of the AAD's Acne Guideline Workgroup. "This update provides evidence-based recommendations for dermatologists and other clinicians caring for patients with acne." Acne affects 85% of adolescents and can also often begin or continue in adulthood, especially in women. Post this Updates to the management of acne vulgaris provides 18 evidence-based recommendations for topical, systemic, and physical treatment methods, including newly approved therapeutic options, and 5 good practice statements. Strong recommendations were made for the use of the following: Topical benzoyl peroxide to reduce the amount of acne-causing bacteria on the skin. Topical retinoids (e.g. adapalene, tretinoin, tazarotene, trifarotene) to help unclog pores and reduce inflammation. Oral antibiotics, such as oral doxycycline, and topical antibiotics to reduce the amount of acne-causing bacteria on the skin and lessen inflammation. Combinations of topical benzoyl peroxide, retinoids, or the above antibiotics. Employing best practices in guideline development, the multidisciplinary workgroup also issued 5 good practice statements. When managing acne with topical medications, the guidelines recommend combining multiple different treatment types, as this can lead to better results. The guidelines recommend limiting use of oral antibiotics when possible to reduce the development of antibiotic resistance and other antibiotic-associated complications. It is recommended that topical and oral antibiotics are used simultaneously with benzoyl peroxide to prevent the development of antibiotic resistance. For patients with larger acne bumps, the guidelines recommend injectable corticosteroids as a potential option for more rapid relief of inflammation and pain. For patients with severe acne or for patients who have failed standard treatment with oral or topical therapy, the guidelines recommend isotretinoin. Additionally, the guidelines provide conditional recommendations. Conditional recommendations apply to most patients, but the most appropriate action may differ depending on individual patient factors. Topical clascoterone, which addresses hormonal causes of acne. Topical salicylic acid to unclog pores and exfoliate the skin. Topical azelaic acid to unclog pores, kill bacteria, and fade dark spots that may continue when an acne spot clears. Oral minocycline or sarecycline to reduce the amount of acne-causing bacteria on the skin and lessen inflammation. Hormonal therapies such as combined oral contraceptives or spironolactone to address hormonal causes of acne. Available evidence was insufficient to develop recommendations for procedures such as chemical peels, laser and light-based devices, microneedling, as well as for dietary changes, or alternative therapies such as vitamins or plant-based products. Additionally, a conditional recommendation against adding broadband light, intense pulsed light, to adapalene 0.3% gel. "Board-certified dermatologists are on the forefront of new and exciting advances in the treatment of acne," said Dr. Barbieri. "We are able to offer our patients with acne more options than ever before as we work to address their concerns and determine the most effective treatment plan possible. Just as important, dermatologists must have access to all available therapeutic options." Since there are a variety of treatment options for acne and treatment plans are not one-size-fits-all, it is important to partner with a board-certified dermatologist to decide which options work best for you. To find a board-certified dermatologist in your area, visit aad.org/findaderm. More Information Acne resource center Acne treatment AAD B-Roll Library About the AAD Headquartered in Rosemont, Ill., the American Academy of Dermatology, founded in 1938, is the largest, most influential and most representative of all dermatologic associations. With a membership of more than 20,800 physicians worldwide, the AAD is committed to advancing the diagnosis and medical, surgical, and cosmetic treatment of the skin, hair, and nails; advocating high standards in clinical practice, education and research in dermatology; and supporting and enhancing patient care because skin, hair, and nail conditions can have a serious impact on your health and well-being. For more information, contact the AAD at (888) 462-DERM (3376) or aad.org. Follow @AADskin on Facebook, TikTok, Pinterest and YouTube and @AADskin1 on Instagram. SOURCE American Academy of Dermatology